MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER Drug Patent Profile

Which patents cover Meropenem And Sodium Chloride In Duplex Container, and what generic alternatives are available?

Meropenem And Sodium Chloride In Duplex Container is a drug marketed by B Braun Medical and is included in one NDA.

The generic ingredient in MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER is meropenem. There are thirty-two drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the meropenem profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Meropenem And Sodium Chloride In Duplex Container

A generic version of MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER was approved as meropenem by ACS DOBFAR on October 26^th, 2011.

Summary for MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	5,335
DailyMed Link:	MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER at DailyMed

Pharmacology for MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

Drug Class

Penem Antibacterial

US Patents and Regulatory Information for MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
B Braun Medical	MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER	meropenem	POWDER;INTRAVENOUS	202106-002	Apr 30, 2015		RX	Yes	Yes
B Braun Medical	MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER	meropenem	POWDER;INTRAVENOUS	202106-001	Apr 30, 2015		RX	Yes	Yes

Last updated: July 29, 2026

Meropenem and Sodium Chloride in Duplex Container: Market Dynamics and Financial Trajectory for Hospital IV Antibiotic Sales

Meropenem and sodium chloride in a duplex container is an IV hospital antibiotic mix that tracks broad inpatient acuity and hospital purchasing cycles rather than patent-driven category expansion. The financial trajectory is dominated by (1) seasonal and case-mix demand for broad-spectrum carbapenems, (2) price compression from multisource generics and label-to-label competition in hospital formularies, and (3) tender-driven gross margin volatility in US institutional procurement. Revenue growth, where it exists, has come mainly from volume retention and conversion within accounts through supply reliability and contracted pricing, not from new-to-market clinical differentiation.

At a high level: market growth in this segment is constrained by carbapenem maturity, substitution into multiple equivalent presentations, and ongoing competitive pressure from other injectable meropenem products in common dosing sizes. Duplex container formats reduce administration friction and can support formulary preference, but they rarely prevent price erosion in commoditized hospital IV antibiotics.

Because “duplex container” is a presentation attribute, this market behaves like a packaging-optimized generic-equivalent product line under institutional purchasing, with financial outcomes driven by contract wins/losses and manufacturing execution rather than exclusivity.

---

How does the US market size and demand for IV meropenem and sodium chloride in hospital supply chains move?

Featured snippet answer: Demand tracks inpatient respiratory, intra-abdominal, complicated UTI, and sepsis case volume, with procurement tied to ID cycle formularies and group purchasing organization (GPO) contracts. Volatility is driven more by patient census and tender timing than by new clinical indications.

Key demand drivers in hospital IV antibiotics

• Inpatient case mix: meropenem use scales with severe infections where broad Gram-negative coverage is required.
• Sepsis protocols: adoption of sepsis pathways drives early empiric broad-spectrum antibiotic use, then de-escalation.
• Hospital antimicrobial stewardship: stewardship can reduce duration and shift to narrower agents, but carbapenems remain a core option for resistant Gram-negative pathogens.
• Seasonality and respiratory surges: ICU admissions and ventilator-associated infections can lift carbapenem usage.
• Supply stability: shortages in upstream API or sterile fill-finish can temporarily shift utilization toward the most reliable suppliers, even if pricing is not the lowest.

Procurement mechanics that shape revenue

Hospital sales of injectable antibiotics are typically governed by:

• GPO participation and contract tiers: listing status impacts order volume.
• Quarterly or semi-annual tender cycles: revenue is lumpy.
• WAC-to-contract discount structure: margins depend on net pricing after rebates and tender-specific concessions.
• Bid defense and formulary conversion: incumbent packs are favored unless there is a clear cost or supply advantage.

---

What market dynamics drive price and gross margin trends for meropenem IV injections, including duplex container SKUs?

Featured snippet answer: Price compression is the base case. Gross margin is pulled by net price concession pressure and offset by packaging-led differentiation that wins contracts on usability and supply continuity.

Price dynamics in mature carbapenems

• Generic entry and substitution: meropenem’s chemical identity makes interchangeability straightforward at the hospital level.
• Tender-led discounting: suppliers bid aggressively; net price can fall faster than list price.
• Freight and sterile packaging costs: duplex containers and sterile handling influence COGS and can swing margin when resin, glass/plastic components, and sterile fill labor change.
• Inventory and shortage effects: when supply tightens, net prices often stabilize or rise temporarily; when supply normalizes, rebates and discounts resume.

Duplex container as a competitive variable

A duplex container format is mainly a presentation and usability differentiator. That can:

• reduce preparation steps for nursing staff,
• improve administration workflow,
• support bundled ordering and inventory handling.

This usually affects win rate in contracting, not category-level pricing power.

---

How has the financial trajectory of meropenem injectable sales typically evolved, and what timeline patterns matter?

Featured snippet answer: The “shape” is usually a mature-product plateau with episodic step-downs around large competitor bid cycles, plus short-term spikes during supply disruptions or infection surges.

Common revenue patterns in hospital antibiotics

• Pre- and post-tender re-bids: revenue declines often appear shortly after contracts reset.
• Portfolio reshuffling: some manufacturers consolidate SKUs by dose strength or presentation to rationalize inventory and reduce manufacturing complexity.
• Capacity reallocation: if a plant line is down, sales can shift to alternative presentations, temporarily preserving volume.
• Stewardship-driven utilization shifts: volume growth can flatten if stewardship reduces empiric use of broad agents.

Financial KPIs used by institutional pharma teams

• Net sales per administered dose (not just units)
• Net price per vial/bottle equivalents after contract discounts
• Gross margin after manufacturing variance
• Share of tender awards in major ID accounts
• Backorder days and on-time delivery (often tied to contract renewal)

---

What competitive landscape determines which manufacturers sell meropenem and sodium chloride in duplex container formats?

Featured snippet answer: Competition is multi-source and contract-driven, dominated by branded history and multiple generic manufacturers offering equivalent meropenem IV presentations. Duplex container variants primarily differentiate logistics and usability.

Competitor set structure (how the market is won)

• Incumbent generic suppliers with established GPO contracts
• Manufacturers with best-fill-finish reliability and supply chain performance
• Regional suppliers who win via bid pricing in specific purchasing groups
• Portfolio players who can cross-sell companion IV antibiotics and win bundled formulary placements

Positioning levers that matter financially

• contract price competitiveness and ability to sustain it,
• supply continuity during manufacturing transitions,
• ability to support hospital pharmacy workflow and education,
• readiness for label and packaging variation across dose strengths.

---

What is the Orange Book status and how does it affect market entry risk for meropenem in duplex container packaging?

Featured snippet answer: The duplex container presentation does not create a new exclusivity category by itself. Orange Book status, where applicable, governs patent and exclusivity around specific products, not packaging alone.

Practical implications for entry risk

• If the product is no longer under drug-substance or composition patents, entry risk is driven by remaining formulation, method, or device/packaging patents tied to a specific NDA or ANDA.
• If multiple ANDAs exist, price competition is already structurally present.

Because this analysis depends on the specific NDA/ANDA tied to “meropenem and sodium chloride in duplex container,” the Orange Book status cannot be mapped reliably from the presentation descriptor alone.

---

Which patents typically protect meropenem IV products, and what categories of IP create real barriers beyond basic composition of matter?

Featured snippet answer: For injectable small-molecule antibiotics, meaningful residual barriers tend to be formulation-specific (excipients, concentration, pH), manufacturing process, or specific container/administration formats, not the core active ingredient.

Patent/IP categories that can affect commercial timing

• Formulation and stability patents
  • pH targets, buffering systems, solubilizers
  • stability shelf-life and in-use time claims
• Manufacturing process patents
  • sterile filtration, lyophilization or solution fill steps
  • impurity profile targets and control strategies
• Container closure or delivery system patents
  • packaging compatibility, transfer/administration device constraints
  • duplex container-specific assembly or venting features
• Method-of-use patents
  • less common for broad IV antibiotics in modern practice, but can exist for specific dosing regimens

---

When does exclusivity or patent protection lose effect for meropenem and sodium chloride duplex container products?

Featured snippet answer: Exclusivity timelines in mature injectable antibacterials typically end decades after initial active ingredient development; remaining competitive timing is driven by any late-filed formulation or packaging patents and by device/presentation-specific claims tied to the NDA/ANDA.

This cannot be converted into dates without mapping the exact product listing (NDA/ANDA number) that corresponds to the “duplex container” presentation.

---

How do Paragraph IV challenges and generic launch scenarios affect meropenem duplex container pricing?

Featured snippet answer: Paragraph IV pressure is a primary driver of sudden net price reductions in hospital tender markets, especially when it brings a new supplier with competitive contracted pricing or improved supply reliability.

Typical effects on the commercial trajectory

• new entrants can bid below incumbent net pricing,
• formulary switch cycles can accelerate if the entrant offers equivalent therapeutic equivalence and reliable supply,
• margin compression can persist through several tender cycles until market share stabilizes.

For this product presentation, timing and occurrence depend on the exact ANDA portfolio and litigation events tied to the specific NDA/ANDA record.

---

What patent litigation or settlements influence the commercial trajectory of meropenem injectable presentations?

Featured snippet answer: Litigation most often shapes launch timing rather than long-run market share, but settlement terms can preserve or accelerate entry in hospital markets.

Settlement-driven outcomes that matter financially

• Covenants not to sue can keep an entrant off-market temporarily or limit launch to specific strengths or presentations.
• Design-around approvals may delay competitive price pressure while allowing eventual market entry.
• Settlement-triggered market entry dates can create sharp revenue step changes.

A litigation map requires the underlying NDA/ANDA and the specific product strengths offered in duplex container form.

---

How does FDA regulatory status (505(b)(2), ANDA, reference product) affect availability and revenue for this duplex container SKU?

Featured snippet answer: Availability and revenue are governed by whether the duplex container product is marketed under an ANDA with adequate supply and whether any remaining regulatory barriers limit distribution.

Regulatory factors that influence sales

• approval status and label comparability,
• supply constraints tied to manufacturing site approvals,
• ability to maintain consistent product shelf-life and packaging integrity,
• substitution policies in hospital formularies aligned with therapeutically equivalent listings.

---

How does meropenem and sodium chloride in duplex container compare with alternative meropenem presentations on cost-to-hospital and conversion rates?

Featured snippet answer: Hospitals generally compare net price, administration workflow, and supply reliability. Duplex container can improve operational convenience, increasing conversion rate in formularies even when net price is not the lowest.

Comparison axes that drive purchasing decisions

• Total administered cost (net unit price plus pharmacy preparation time)
• Fill size and dosing flexibility (dose-strength coverage)
• Preparation time and nursing steps
• Availability during tender horizon
• Stability and handling (in-use time, storage requirements)

In practice, the duplex container format can be the tie-breaker when multiple equivalent meropenem sources compete on near-parity net pricing.

---

What commercial exposure does this product segment face given hospital antimicrobial stewardship and sepsis protocol shifts?

Featured snippet answer: Stewardship pressures can reduce volume growth and increase de-escalation, but sepsis and resistant Gram-negative burden preserve core demand. The biggest exposure is price compression and tender re-bids rather than direct category collapse.

Exposure scenarios that impact revenue

• Volume-down: stewardship reduces empiric carbapenem use or shortens duration.
• Mix-down: preference shifts to other broad-spectrum agents when resistance patterns support it.
• Price-down: new multisource competitive entries compress net sales.
• Supply-up: stable supply can preserve share even in a flat demand environment.

---

Key Takeaways

• Meropenem and sodium chloride in duplex container is a hospital IV antibiotic segment where financial trajectory is shaped by tender-driven net pricing, supply reliability, and operational workflow advantages of the packaging format.
• Category demand tracks inpatient infection acuity and sepsis-related prescribing more than it tracks presentation-specific differentiation.
• Duplex container can raise formulary conversion rates, but it does not typically prevent the margin and revenue compression that comes with multisource meropenem competition.
• Exclusivity, Orange Book status, patent expiration, and Paragraph IV litigation timing cannot be translated into dates from the presentation descriptor alone; commercial risk for this SKU depends on the underlying NDA/ANDA listing and any presentation-specific patents.
• The practical investment and licensing question is whether a supplier has durable contract share (and supply performance) that offsets price compression over multiple tender cycles.

---

FAQs

1) What drives quarter-to-quarter revenue volatility for IV antibiotics like meropenem in hospital contracting?
Tender award timing, backorder fill rates, and contract re-bids tied to GPO cycles.

2) Do duplex containers for meropenem change therapeutic interchangeability in hospital formularies?
They typically do not change therapeutics, but they can affect workflow convenience and conversion when net prices are close.

3) What KPIs best predict whether a meropenem supplier will defend market share?
Net price per administered equivalent, on-time delivery, backorder days, and tender win rate in priority accounts.

4) How do generic launches usually affect net pricing for mature hospital injectables?
They often trigger step-down net pricing through competitive bid pricing and renewed formulary switching.

5) What risk matters most to long-term profitability: demand elasticity or price compression?
Price compression and contract discount pressure usually dominate for mature multisource hospital antibiotics.

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA. Drugs@FDA. U.S. Food and Drug Administration.
3. FDA. FDA Labeling Resources (PLR) and prescribing information repository. U.S. Food and Drug Administration.
4. U.S. Food and Drug Administration. Guidance for Industry: Questions and Answers about Biosimilars and CDER Drug Development Tools. U.S. FDA.